Sugi Predict

Sugi Predict / Compounds / SCHEMBL244798

SCHEMBL244798

SCHEMBL244798

[c]1n[nH]c2cccc(-c3ncc[nH]3)c12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CSNK1A1 P48729 1/20 0.41
▸ TYRO3 Q06418 1/20 0.41
▸ DYRK1B Q9Y463 1/20 0.41
▸ NISCH Q9Y2I1 2/20 0.40
▸ MTOR P42345 1/20 0.40
▸ ADK P55263 1/20 0.40
▸ IDO1 P14902 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ADRA1A P35348 1/20 0.35
▸ MC4R P32245 2/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ ADRA2A P08913 3/20 0.32
▸ CASP6 P55212 1/20 0.32
▸ PDE3B Q13370 1/20 0.31
▸ PDE3A Q14432 1/20 0.31
▸ SCN9A Q15858 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ PIK3CD O00329 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1812287 0.74 NPC1 (0.54) ALDH1A1KDM4E
SCHEMBL26259965 0.72 NISCH (0.54) CSNK1A1TYRO3DYRK1BNISCHMTOR
SCHEMBL2353932 0.71 METAP2 (0.47) CSNK1A1TYRO3DYRK1BIDO1ALDH1A1
SCHEMBL9287236 0.71 NISCH (0.64) CSNK1A1TYRO3DYRK1BNISCHMTOR
SCHEMBL2410047 0.71 METAP2 (0.40) NISCHADRA1ASCN9AKDM4E
SCHEMBL28382846 0.70 CSNK1A1 (0.56) CSNK1A1TYRO3DYRK1BNISCHMTOR
SCHEMBL27996777 0.70 CSNK1A1 (0.42) CSNK1A1TYRO3DYRK1BNISCHMTOR
SCHEMBL4190285 0.70 CSNK1A1 (0.42) CSNK1A1TYRO3DYRK1BNISCHMTOR
SCHEMBL14886257 0.69 NISCH (0.61) CSNK1A1TYRO3DYRK1BNISCHMTOR
SCHEMBL28426754 0.69 BRD4 (0.46) CSNK1A1TYRO3DYRK1BNISCHMTOR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004246-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2012-01-05 — — US claimed
JP-2010522721-A — — 2010-07-08 — — JP claimed
JP-2010522719-A — — 2010-07-08 — — JP claimed
JP-2010522722-A — — 2010-07-08 — — JP claimed
US-20100130516-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-05-27 — — US claimed
US-20100105705-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2010-04-29 — — US claimed
EP-2144911-A2 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NeuroSearch AS (DK) 2010-01-20 — — EP claimed
EP-2142547-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2010-01-13 — — EP claimed
EP-2142545-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NeuroSearch A/S (DK) 2010-01-13 — — EP claimed
WO-2008116914-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-10-02 — — WO claimed
WO-2008116912-A2 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-10-02 — — WO claimed
WO-2008116910-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS NEUROSEARCH A/S (DK) 2008-10-02 — — WO claimed
EP-1904465-A1 METHOD OF SYNTHESIS OF IMIDAZOLE-AMINO ACID DERIVATIVES AND RELATED COMPOUNDS JANSSEN PHARMACEUTICA N.V. (BE) 2008-04-02 — — EP claimed
WO-2007005000-A1 METHOD OF SYNTHESIS OF IMIDAZOLE-AMINO ACID DERIVATIVES AND RELATED COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2007-01-11 — — WO claimed
CN-118271233-A Nilaparil manufacturing method 特沙诺有限公司 2024-07-02 — — CN disclosed
CN-118284434-A Compositions and methods for skipping exon 45 in duchenne muscular dystrophy 恩特拉达治疗学股份有限公司 2024-07-02 — — CN disclosed
CN-118215504-A Compounds and methods for skipping exon 44 in duchenne muscular dystrophy 恩特拉达治疗学股份有限公司 2024-06-18 — — CN disclosed
WO-2015117923-A1 LEWIS ACID ELECTROCATALYSED FUEL CELL & BATTERY IMPERIAL INNOVATIONS LIMITED (GB) 2015-08-13 — — WO disclosed
EP-2838538-A1 CYCLOPROPANECARBOXYLATE ESTERS OF PURINE ANALOGUES Annji Pharmaceutical Co., Ltd. (TW) 2015-02-25 — — EP disclosed
WO-2013158367-A1 CYCLOPROPANECARBOXYLATE ESTERS OF PURINE ANALOGUES Annji Pharmaceutical Co., Ltd. (TW) 2013-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004246-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNJ5, KCNJ3 CSNK1A1 1026/4885TYRO3 3295/4885DYRK1B 2756/4885
US-20100105705-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNJ5, KCNJ3 CSNK1A1 1026/4885TYRO3 3295/4885DYRK1B 2756/4885
US-20100130516-A1 PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS KCNJ2, KCNJ5, KCNJ3 CSNK1A1 1026/4885TYRO3 3295/4885DYRK1B 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.